CANCIDAS Powder for solution for infusion Ref.[6558] Active ingredients: Caspofungin

Source: European Medicines Agency (EU)  Revision Year: 2018  Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Product name and form

CANCIDAS 50 mg powder for concentrate for solution for infusion.

CANCIDAS 70 mg powder for concentrate for solution for infusion.

Pharmaceutical Form

Powder for concentrate for solution for infusion.

Before reconstitution, the powder is a white to off-white-compact, powder.

Qualitative and quantitative composition

CANCIDAS 50 mg powder for concentrate for solution for infusion: Each vial contains 50 mg caspofungin (as acetate).

Excipients with known effect: Each 50 mg vial contains 35.7 mg of sucrose.

CANCIDAS 70 mg powder for concentrate for solution for infusion: Each vial contains 70 mg caspofungin (as acetate).

Excipients with known effect: Each 70 mg vial contains 50.0 mg of sucrose.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Caspofungin

Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of Glarea lozoyensis. Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.

List of Excipients

Sucrose
Mannitol
Glacial acetic acid
Sodium hydroxide (to adjust the pH)

Pack sizes and marketing

CANCIDAS 50 mg powder for concentrate for solution for infusion: 10 ml Type I glass vial with a grey butyl stopper and a plastic cap with a red aluminium band.

CANCIDAS 70 mg powder for concentrate for solution for infusion: 10 ml Type I glass vial with a grey butyl stopper and a plastic cap with an orange aluminium band.

Supplied in packs of 1 vial.

Marketing authorization holder

Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Marketing authorization dates and numbers

EU/1/01/196/001

EU/1/01/196/003

Date of first authorisation: 24 October 2001

Date of latest renewal: 07 September 2011

Drugs

Drug Countries
CANCIDAS Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, Ireland, Japan, Lithuania, Mexico, Nigeria, Netherlands, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.